Systemic Bevacizumab for Recurrent Respiratory Papillomatosis: A Scoping Review from 2009 to 2022

Background: Respiratory recurrent papillomatosis (RRP) is a fatal disease with no known cure. In severe RRP cases, systemic bevacizumab (SB) could be used as adjuvant therapy. Objective: This study aims to determine the extent and type of evidence in relation to the clinical outcomes of RRP after SB...

Disgrifiad llawn

Manylion Llyfryddiaeth

Prif Awduron:	Laura Torres-Canchala, Daniela Cleves-Luna, Oriana Arias-Valderrama, Estephania Candelo, María Angelica Guerra, Harry Pachajoa, Manuela Olaya
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	MDPI AG 2022-12-01
Cyfres:	Children
Pynciau:	adjuvant therapy child adult adult-onset recurrent respiratory papillomatosis juvenile-onset papillomatosis recurrent respiratory papillomatosis systemic bevacizumab treatment
Mynediad Ar-lein:	https://www.mdpi.com/2227-9067/10/1/54
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!